CompletedNCT00762268
SAMe supplement for treatment-resistant depression in bipolarity
About this title
A Trial of SAMe for Treatment-Resistant Bipolar Depression
Read the official source —Researchers compared SAMe and placebo to find out how the approaches affected depression symptoms in people with bipolarity during a depressive episode.
Medication studyAges 18–65United States
Understand this study
What did researchers investigate?
Researchers compared SAMe and placebo to find out how the approaches affected depression symptoms in people with bipolarity during a depressive episode.
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- BelmontSee all locations and recruitment
Study information
Study start dateSeptember 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 23
- Sponsor
- Mclean Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00762268
- Official title
Show the full official title
Intermittent-Dose Oral SAMe (S-adenosyl-L-methionine) in Persistent and Treatment-Refractory Bipolar Depression: A Double-Blind Pilot Trial With an Optional Open-label Follow-up
Get this study by email
Recruitment & locations
CompletedBelmont
Questions about this study
What did researchers investigate?
Researchers compared SAMe and placebo to find out how the approaches affected depression symptoms in people with bipolarity during a depressive episode.
Who is behind this study?
The study sponsor is Mclean Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including SAMe and Placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
